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  Purpose: Inflammation acts as a driving force for the 
development of cancer. Multiple lines of evidence sug-
gest that nonsteroidal anti-inflammatory drugs, espe-
cially those that specifically target cyclooxygenase-2  
(COX-2), are effective in preventing certain cancers. The 
present study was aimed at investigating the antitumor 
promoting potential of celecoxib in chemically induced 
mouse skin tumorigenesis, as well as elucidating the 
underlying molecular mechanisms.
  Materials and Methods: To study the antitumor 
promoting effects of celecoxib, we used the classical 
two-stage mouse skin tumorigenesis model that involves 
initiation with a single application of 7,12-dimethylbenz
[α]anthracene (DMBA) followed by promotion with 
repeated applications of 12-O -tetradecanoylphorbol-13- 
acetate (TPA). The effects of celecoxib on the expression 
of COX-2, vascular endothelial growth factor (VEGF), p65  
and the different isoforms of CCAAT/enhancer binding 
protein (C/EBP) were examined by performing W estern 
blot analysis. Electrophoretic mobility gel shift assay was 
used to examine the effects of celecoxib on the TPA- 
induced DNA binding activities of various transcription 
factors. 
  Results: Our study revealed that topical application of 
celecoxib (10μmol) significantly reduced the multiplicity 
of papillomas in DMBA-initiated and TPA-promoted mouse
skin. Pretreatment with celecoxib also diminished the 
expression of COX-2 and VEGF in the mouse skin pa-
pillomas. Pretreatment with celecoxib attenuated DNA 
binding of transcription factor (C/EBP) in the TPA- 
stimulated mouse skin. Moreover, celecoxib suppressed 
the TPA-induced nuclear expression of C/EBPδ, but not 
C/EBPβ, in mouse skin in vivo.
  Conclusion: Our study demonstrates the inhibitory 
effects of celecoxib on mouse skin tumor promotion, 
which was associated with a decreased expression of 
COX-2 and VEGF, as well as inhibition of C/EBP acti-
vation. (Cancer Res Treat. 2006;38:152-158)
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INTRODUCTION
  A substantial body of evidence suggests that chronic 
inflammation acts as a driving force for the development of 
cancer (1). However, the cellular and molecular mechanisms 
that underlie the tumor-promoting effect of inflammation have 
not been fully elucidated. One of the frequently used animal 
models to study the mechanistic link between inflammation and 
the development of cancer is the classical two-stage mouse skin 
tumorigenesis model that involves an initiation and promotion 
scheme. According to this model, initiation of tumorigenesis is 
achieved by topical application of a relatively low dose of a 
genotoxic carcinogen such as 7,12-dimethylbenz[α]anthracene 
(DMBA), whereas promotion can be induced by repeated 
applications of a tumor promoter, including 12-O-tetradeca-
noylphrobol 13-acetate (TPA). Several previous studies have 
supported the concept of a tumor-promoting role for inflam-
mation in mouse skin carcinogenesis (2～4). It has been 
reported that the transgenic overexpression of a pro-inflam-
matory enzyme cyclooxygenase-2 (COX-2), which is involved 
in the biosynthesis of prostaglandins (PGs) from arachidonic 
acid, sensitizes mouse skin for promotion of tumor (3). On the 
other hand, genetic ablation of cox-2 protects against che-
mically induced mouse skin tumorigenesis (4). Several studies 
have suggested that inflammatory mediators including the 
different PGs (e.g., PGE2, PGF2α and 15-deoxy-Δ12,14-PGJ2) are 
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functionally related to mouse skin tumor promotion (2,5). 
  Topical application of TPA has been shown to induce the 
expression of COX-2 and its mRNA transcript in mouse skin 
(6) by activating the intracellular signaling that's mediated by 
various transcription factors and a series of upstream kinases. 
The 5'-flanking region of the cox-2 gene contains a canonical 
TATA box and the binding sequences for various transcription 
factors, including nuclear factor-kappaB (NF-κB), CCAAT/ 
enhancer binding protein (C/EBP), cyclic AMP response 
element binding protein-binding protein (CREB), activator 
protein-1 (AP-1), etc. Inappropriate activation of these trans-
cription factors often leads to the overexpression of cox-2. 
  Accumulating evidence from clinical, epidemiological and 
laboratory-based studies has suggested that non-steroidal 
anti-inflammatory drugs (NSAIDs) are effective in preventing 
certain cancers. Celecoxib, a selective COX-2 inhibitor 
developed for the treatment of inflammatory ailments, has been 
reported to reduce the burden of polyps in patients with familial 
adenomatous polyposis (7). Moreover, celecoxib inhibits 
experimentally induced tumorigenesis in several animal models 
(reviewed in 8, and see references therein), including azoxyme-
thane-induced colon tumorigenesis in F344 rats, DMBA- 
induced rat mammary carcinogenesis, ultraviolet (UV) radia-
tion-induced mouse skin tumor formation and N-butyl-N-(4- 
hydroxybutyl) nitrosamine-induced urinary bladder carcino-
genesis in male B6D2F1 mice and female Fischer 344 rats. We 
have recently reported that topical application of celecoxib 
downregulates the TPA-induced COX-2 expression in mouse 
skin by blocking the activation of AP-1 via inactivation of the 
upstream p38 mitogen-activated protein (MAP) kinase (9). The 
present study was aimed to investigate the effects of celecoxib 
on TPA-induced tumor promotion and to determine the 
underlying molecular mechanisms in mouse skin in vivo.
MATERIALS AND METHODS
    1) Materials
  Celecoxib (CelebrexTM) was supplied from Pharmacia  
Korea. TPA was purchased from Alexis Biochemicals (San 
Diego, CA). Rabbit polyclonal COX-2 antibody was procured 
from Cayman Chemical Co. (Ann Arbor, MI). Primary 
antibodies for vascular endothelial growth factor (VEGF), 
C/EBPδ, C/EBPβ and p65/RelA were purchased from Santa 
Cruz Biotechnology (Santa Cruz, CA). Anti-actin antibody was 
purchased from Sigma Chemical Company (St Louis, MO). 
Anti-rabbit and anti-goat horseradish peroxidase conjugated- 
secondary antibodies were the products of Zymed Laboratories 
(San Francisco, CA). The enhanced chemiluminescence (ECL) 
detection kit and [γ-32P]ATP were purchased from GE 
Healthcare (Buckinghamshire, UK).
    2) Animal treatment
  Female ICR mice (6～7 weeks of age) were purchased from 
the Dae-Han/Biolink Experimental Animal Center (Daejeon, 
Korea). The animals were housed in climate-controlled quarters 
(24oC at 50% humidity) with a 12 h light/12 h dark cycle. The 
dorsal side of their skin was shaved using an electric clipper, 
and only those animals in the resting phase of the hair cycle 
were used in all experiments. TPA (10 nmol) and the respective 
doses of celecoxib were dissolved in 0.2 ml acetone and 
topically applied to the dorsal shaven area. 
    3) Two-stage mouse skin carcinogenesis
  Female ICR mice were randomly divided into four groups, 
each consisting of 25 animals. Mice belonging to groups II, III 
and IV were treated with DMBA (0.2μmol) dissolved in 0.2 
ml acetone：DMSO (85：15, v/v) on their shaven backs. The 
control mice in group I were treated with the same volume of 
solvent. One week after the initial treatment with DMBA, TPA 
(10 nmol/0.2 ml acetone) was topically applied to the animals 
in groups II, III and IV twice a week until termination of the 
experiment. Celecoxib was topically applied 30 min before each 
of the TPA treatments in groups III and IV at a dose of 1 and 
10μmol, respectively. Starting at 1 week following treatment 
with the promoter, tumors of at least 1 mm diameter were 
counted every week until the termination of the experiment. 
The results were expressed as the percentage of papilloma- 
bearing mice (incidence) and the average number of papillomas 
per mouse (multiplicity).
    4) Western blot analysis
  The mouse skin papillomas were collected, incised and 
washed with ice-cold phosphate-buffered saline (PBS). In other 
short-term experiments, the shaven backs of the female ICR 
mice were topically treated with celecoxib (1 or 10μmol) 30 
min before application of TPA (10 nmol); then they were killed 
by cervical dislocation either 1 or 4 h later. The collected 
papillomas or epidermis were homogenized in 800μl of 
ice-cold lysis buffer [150 mM NaCl, 0.5% Triton-X 100, 50 
mM Tris-HCl (pH 7.4), 20 mM EGTA, 1 mM DTT, 1 mM 
Na3VO4 and a protease inhibitor cocktail tablet]. The lysates 
were centrifuged at 14,800×g for 15 min. The supernatant was 
collected and the total protein concentration was quantified by 
using a BCA protein assay kit. The cell lysates (30～50μg 
protein) were boiled in SDS sample buffer for 5 min before 
electrophoresis on 10～12% SDS-polyacrylamide gel. After 
transfer to a PVDF membrane, the blots were blocked with 5% 
fat-free dry milk-PBST buffer (PBS containing 0.1% Tween 20) 
for 1 h at room temperature and then they were washed with 
PBST. The membranes were incubated for overnight at 4oC 
with 1：1,000 dilutions of the primary antibodies for COX-2, 
VEGF, C/EBPδ and C/EBPβ, and also with a 1：500 dilution 
of p65/RelA. The blots were washed three times with PBST 
at 5-min intervals followed by incubation with an 1：5,000 
dilution of the respective horseradish peroxidase conjugated- 
secondary antibodies (rabbit or goat) for 1 h, and then they 
were again washed in PBST for three times. The transferred 
proteins were visualized with an ECL detection kit according 
to the manufacturer's instructions.
    5) Preparation of nuclear extracts from the mouse skin
  The nuclear extract from mouse skin was prepared as 
previously described (6). In brief, the scraped dorsal skin was 
homogenized in 800μl of hypotonic buffer A [10 mM HEPES 
(pH 7.8), 10 mM KCl, 2 mM MgCl2, 1 mM DTT, 0.1 mM 
EDTA and 0.1 mM phenylmethylsulfonylfluoride (PMSF)]. 80 
μl of 10% Nonidet P-40 (NP-40) solution was added to the 
homogenates, and the mixtures were then centrifuged for 2 min 
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Fig. 1. Celecoxib inhibits the promotion of mouse skin tumor. male ICR mice were treated with 0μmol (○) 1μmol (▼) or 10μmol 
(▽) μmol of celecoxib dissolved in 0.2 ml acetone or they were treated with the solvent alone 30 min prior to each topical application 
of TPA (10 nmol/0.2 ml acetone) after initiation with DMBA (0.2 μmol in 0.2 ml acetone). The control animals (●) were treated with 
acetone in lieu of TPA. Each treatment group consisted of 25 mice. (A) Comparison of the average numbers of papillomas per mouse 
in the different treatment groups. The multiplicity of papillomas in the celecoxib (10μmol) pretreated group is significantly lower than 
that observed in the group treated with DMBA plus TPA only (p＜0.05). (B) The percent incidence of papillomas in the different treatment 
groups.
at 14,000×g. The supernatant was collected as a cytosolic 
fraction. The precipitated nuclei were washed once with 500 
μl of buffer A plus 40μl of 10% NP-40, centrifuged, 
resuspended in 200μl of buffer C [50 mM HEPES (pH 7.8), 
50 mM KCl, 300 mM NaCl, 0.1 mM EDTA, 1 mM DTT, 0.1 
mM PMSF and 20% glycerol); then they were centrifuged for 
5 min at 14,800×g. The supernatant containing nuclear 
proteins was collected and stored at -70oC after determination 
of the protein concentrations.
    6) Electrophoretic mobility shift assay (EMSA)
  The EMSA for DNA binding of the different transcription 
factors was performed by using a DNA-protein binding 
detection kit according to the manufacturer’s protocol (GIBCO 
BRL, Grand Island, NY). Briefly, oligonucleotides harboring 
the binding sites for NF-κB (5’-GATCGAGGGGGACTTTC 
CCAGC-3’) and C/EBP (5’-AGAGATTGCCTGA CGTCAGA 
GAGCTAG-3’) were labeled with [γ-32P] ATP by using T4 
polynucleotide kinase, and these oligonucleotides were purified 
on a Nick column (GE Healthcare, UK). The binding reaction 
was carried out in 25μl of a mixture containing 5μl of 
incubation buffer [10 mM Tris-HCl (pH 7.5), 100 mM NaCl, 
1 mM DTT, 1 mM EDTA, 4% glycerol and 0.1 mg/ml 
sonicated salmon sperm DNA], 10μg of nuclear extracts and 
100,000 cpm of the [γ-32P]ATP-labeled oligonucleotide. After 
50 min incubation at room temperature, 2μl of 0.1% bromo-
phenol blue was added, and the samples were electrophoresed 
through 6% non-denaturing polyacrylamide gel at 150 V in a 
cold room for 2 h. The gel was finally dried and exposed to 
X-ray film.
    7) Statistical evaluation
  The values are expressed as the mean±S.D. of at least three 
independent experiments. Statistical significance was deter-
mined by Student’s t-test and a p-value of less than 0.05 was 
considered to be statistically significant.
RESULTS
    1) Suppression of DMBA-initiated and TPA-promoted 
mouse skin tumorigenesis by celecoxib
  Our previous study demonstrated the suppression of the 
TPA-induced COX-2 expression by celecoxib (9), which 
prompted us to examine the effect of this COX-2 specific 
inhibitor on the promotion of mouse skin tumor. Celecoxib (1 
or 10μmol) was applied to the DMBA-initiated dorsal skin of 
female ICR mice 30 minutes prior to each topical application 
of TPA for twice a week for 18 weeks. The onset of papillomas 
in the DMBA-initiated mouse skin occurred 8 weeks after TPA 
treatment (Fig. 1). At the 18th week, all the animals in the 
DMBA plus TPA-treated group developed papillomas at about 
18 tumors/mouse. Pretreatment with celecoxib at a dose of 10 
μmol significantly (p＜0.05) lowered the multiplicity of the 
papillomas (Fig. 1A), while the tumor incidence was only 
slightly reduced (Fig. 1B).
    2) Inhibitory effects of celecoxib on the expression of 
COX-2 and VEGF in mouse skin papillomas
  Since COX-2 has been implicated in tumorigenesis (8), we 
examined the effect of celecoxib on the expression of COX-2 
in mouse skin papillomas. Our study revealed that the expre-
ssion level of COX-2 was elevated in the papillomas collected 
from the DMBA plus TPA treated group. Celecoxib (10μmol) 
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Fig. 2. Celecoxib diminishes the ex-
pression of COX-2 and VEGF in 
mouse skin papillomas. Whole tissue 
extracts or tumor extracts that were 
prepared from both control and treated 
animals were subjected to Western 
blot analysis for checking the levels 
of COX-1, COX-2 (A) and VEGF 
(B). Quantification of the COX-2 and 
VEGF immunoblotting was performed 
via an image densitometer, and the 
relative band intensity was normalized 
to that of actin; this was followed by 
statistical analysis (C). *p＜0.001 
(Control vs. DMBA plus TPA-treated 
group); †p＜0.01 (DMBA plus TPA- 
treated group vs DMBA plus cele-
coxib plus TPA- treated group).
pretreatment significantly (p＜0.01) reduced the expression of 
COX-2 in the papillomas, while the expression of the house- 
keeping enzyme COX-1 remained largely unchanged (Fig. 2A, 
2C).
  An elevated expression of COX-2 has also been implicated 
in angiogenesis, which is a cardinal feature of the rapid growth 
of a tumor mass (10,11). One of the principal angiogenic fac-
tors is VEGF, which is a potential target of various anticancer 
agents (12). In the present study, we sought to examine the 
effect of celecoxib on the expression level of VEGF in mouse 
skin papillomas. As shown in Fig. 2B and 2C, mouse skin 
papillomas from the celecoxib pretreated group exhibited a 
significant (p＜0.01) decrease in the expression of VEGF as 
compared to that observed in the papillomas from animals 
treated with only DMBA plus TPA.
    3) Effects of celecoxib on the activation of NF-κB in 
TPA-stimulated mouse skin 
  We have recently reported that celecoxib inhibits COX-2 
expression by blocking the activation of an eukaryotic 
transcription factor AP-1 via the down-regulation of upstream 
p38 MAP kinase in TPA-stimulated mouse skin (9). Besides 
AP-1, NF-κB has been shown to play a key role in regulating 
the expression of COX-2. Therefore, we attempted to examine 
the effect of celecoxib on TPA-induced activation NF-κB in 
mouse skin in vivo. Our study revealed that a single topical 
application of celecoxib (10μmol) failed to affect TPA-induced 
nuclear translocation of an NF-κB subunit protein p65/RelA 
(Fig. 3A) and the DNA binding of NF-κB in mouse skin (Fig. 
3B).
    4) Inhibitory effects of celecoxib on TPA-induced 
C/EBP activation in mouse skin 
  To further identify the molecular targets of celecoxib for 
suppressing tumor promotion and the COX-2 expression in 
TPA-treated mouse skin, we examined the effect of celecoxib 
on the activation of another transcription factor C/EBP 
(NF-IL6), which is known to regulate the COX-2 expression 
(13). Pretreatment with celecoxib (10μmol) diminished the 
TPA-induced DNA binding of C/EBP (Fig. 4A). Celecoxib also 
attenuated the nuclear expression of C/EBPδ, but not C/EBPβ, 
in the TPA-stimulated mouse skin (Fig. 4B). 
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Fig. 3. Effects of celecoxib on TPA-induced NF-κB activation in 
mouse skin. The shaven backs of female ICR mice were treated 
with celecoxib (1 or 10μmol) 30 min prior to topical application 
of 10 nmol TPA. The animals were sacrificed 1 h after the TPA 
treatment, and the epidermal nuclear extracts were prepared as 
described in the Materials and Methods section. (A) The nuclear 
extracts (10μg) were incubated with radio-labeled NF-κB 
oligonucleotide, and NF-κB DNA binding assay was performed 
by EMSA. Lane 1, probe only; Lane 2, acetone control; Lane 3, 
TPA treatment only; Lane 4, celecoxib (1μmol) plus TPA; Lane 
5, celecoxib (10μmol) plus TPA; Lane 6, celecoxib (10μmol) 
alone. (B) The nuclear protein (50μg) was separated by 10% 
SDS-polyacrylamide gel, and immunoblotting was performed by 
using a specific primary antibody to detect p65 protein.
Fig. 4. Celecoxib suppresses TPA-induced DNA binding of C/EBP 
in mouse skin. Animals were treated as described in Fig. 3. (A) 
The nuclear extracts (10μg) were incubated with radio-labeled 
C/EBP oligonucleotide, and the DNA binding assay was done by 
EMSA. Lane 1, probe only; Lane 2, acetone control; Lane 3, TPA 
treatment only; Lane 4, celecoxib (1μmol) plus TPA; Lane 5, 
celecoxib (10μmol) plus TPA; Lane 6, lane 2 plus excess cold 
probe. (B) The nuclear proteins (50μg) were analyzed for the 
expression of C/EBPβ and C/EBPδ.
DISCUSSION
  Chemoprevention is an innovative approach that focuses on 
pharmacological and nutritional interventions to prevent, 
reverse or delay carcinogenesis. The concept of chemopreven-
tion by targeting inflammation has recently been promulgated 
through multiple lines of evidence from preclinical and clinical 
studies (1,14). A wide spectrum of anti-inflammatory sub-
stances, especially selective COX-2 inhibitors, have been shown 
to prevent the onset or progression of various cancers (7,8,14). 
Thus, prolonged intake of aspirin and other NSAIDs have been 
reported to reduce the risk of cancer of different organs 
including the colon and other gastrointestinal organs, breast, 
prostate, lung and skin. Although there is controversy that the 
cardiovascular toxicity of selective COX-2 inhibitors (15) may 
offset the benefits of these agents in cancer chemoprevention, 
recent clinical studies have demonstrated that not all COX-2 
inhibitors are equivalent for provoke cardiac toxicity (16,17). 
Moreover, the European Medicines Agency has concluded that 
COX-2 inhibitors are contraindicated only for those patients 
with established cardiovascular disorders and so they should be 
used with caution in patients with risk factors (18). A nested 
case-control study on a cohort of 469,674 patients revealed that 
the use of rofecoxib and etoricoxib, but not celecoxib, was 
associated with a significantly increased risk of ischemic stroke 
(19). Moreover, a recent cohort study conducted among 74,838 
subjects demonstrated that the risk of cardiovascular events was 
significantly elevated with the use of rofecoxib and it was 
significantly reduced with naproxen, while the use of celecoxib 
did not cause a significant increase or decrease in the 
cardiovascular event rate (15). 
  There is now ample evidence suggesting that one of the 
epigenetic mechanisms involved in the field of carcinogenesis 
is the overamplification of the inflammatory signaling that 
results in aberrant COX-2 induction (8,20). Therefore, COX-2 
has been recognized as a molecular link between inflammation 
and cancer (8,20). To explore the molecular basis of the 
antitumor promoting effect of celecoxib, we have examined the 
effect of celecoxib on the expression of COX-2 in mouse skin 
papillomas. In the present study, the papillomas produced by 
DMBA plus TPA treatment exhibited a significant elevation of 
their COX-2 expression levels, which was diminished by 
celecoxib pretreatment during the promotion stage. Therefore, 
it is plausible to infer that COX-2 is a valid molecular target 
of celecoxib for achieving an antitumor-promoting effect with 
using this selective COX-2 inhibitor. Our previous studies 
demonstrated that single topical application of celecoxib 
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down-regulated the COX-2 expression in mouse skin that had 
been treated with a single dose of TPA (9). Celecoxib, like the 
other NSAIDs, has been developed as a drug that can inhibit 
COX-2-catalyzed reactions. Besides down-regulating the 
COX-2 expression in mouse skin, celecoxib that is topically 
applied at the same dose (10μmol) may also inhibit the catalytic 
activity of this enzyme as well. However, multiple COX-2- 
independent mechanisms that underlie the anticarcinogenic 
effects of celecoxib have also been documented (21). 
  The growth of a solid tumor involves extensive neovas-
cularization, which is promoted by an elevation of VEGF. Skin 
papillomas from the DMBA plus TPA treatment group showed 
an elevated expression of VEGF, but this was suppressed in 
the papillomas from the celecoxib pretreated group; this 
suggests that COX-2 plays an important role for angiogenesis 
during the formation of mouse skin papilloma. Similar to our 
findings, the antiangiogenic effect of celecoxib was evidenced 
by the decreased expression of VEGF in human pancreatic 
cancer cells (22) and the retinas of streptozotocin-induced dia-
betic rats, as well as the reduced secretion and mRNA levels 
of VEGF in human retinal pigment (ARPE-19) cells (23). 
Further investigation is necessary for verifying the reduced 
blood vessel formation in the papillomas from celecoxib-treated 
mouse skin.
  We have previously reported that celecoxib inhibited the 
TPA-induced COX-2 expression in mouse skin by blocking the 
activation of AP-1 via the modulation of p38 MAP kinase (9). 
Besides AP-1, the inappropriate activation of other transcription 
factors such as NF-κB, C/EBP and CREB are also known to 
regulate cox-2 transcription (13), Therefore, we have extended 
our study to examine the effect of celecoxib on the activation 
of other transcription factors, and particularly NF-κB and 
C/EBP, in TPA-stimulated mouse skin in vivo. While celce-
coxib has been shown to suppress NF-κB activation in several 
cell lines, our study shows that TPA-induced NF-κB activation 
in mouse skin remained unaffected by pretreatment with 
celecoxib. 
  The transcription factor C/EBP consists of three major 
isoforms: C/EBPα, C/EBPβ, and C/EBPδ, and these play a 
regulatory role in the induction of COX-2 by bacterial lipo-
polysacharides (LPS) or TPA (24). Therefore, we examined the 
effect of celecoxib on the TPA-induced activation of C/EBP in 
mouse skin. Our results of inducing C/EBP DNA binding and 
the elevated nuclear expression of C/EBPδ in TPA-treated 
mouse skin correlate with those of the previous studies that 
demonstrated an elevation of the nuclear levels of C/EBPδ, but 
not C/EBPα or C/EBPβ, in mouse skin papillomas (13) and 
LPS-stimulated murine macrophages (25). In addition to our 
previous study that reported on inhibition of AP-1 signaling as 
a molecular basis for the chemoprevention by celecoxib (9), the 
present study indicates that C/EBP is another potential target 
of celecoxib in achieving its antitumor promoting effects in 
mouse skin in vivo. It has been demonstrated that celecoxib 
inhibited the phosphorylation as well as catalytic activity of p38 
MAP kinase, which regulates activation of such transcription 
factors as AP-1 and NF-κB in mouse skin (9). It would be 
quite interesting to conduct further research to explore the role 
of p38 MAP kinase for TPA-induced C/EBP activation in 
mouse skin. 
CONCLUSIONS
  In this study, topically applied celecoxib inhibited mouse 
skin tumor promotion. The anti-tumor promotional activity of 
this anti-inflammatory drug appears to be attributed to its 
suppression of COX-2 expression induced by the tumor pro-
moter, TPA. While our previous work addressed the role of 
AP-1 in TPA-induced COX-2 expression in mouse skin, the 
present study suggests C/EBP as another potential transcription 
factor that may regulate COX-2 induction and can hence be a 
potential target of celecoxib.
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